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MTT assay is one of the most prevalent in vitro 
methods that has been used to test CM1 function 
by using 3-[4,5,dimethylthiazol-2-yl]-2,5diphenyl tetra- 
zolium bromide. In our study, we used the following 
mitogens; Concanavalin A as a mitogenic positive 
control, SZcomplex (Saddam College of medicine) and 
Pneumo-23 (Pasteur merieux connaught) vaccine as test 
substances, no mitogens as negative control. 
Our study has it’s own objectives for the application 
of MTI assay. The first objective was the evaluation of 
CM1 level in HNCA patients in comparison with HC 
group via the susceptibility of PBL to be stimulated by 
different mitogenic substances.The second objective was 
the evaluation of using SZcomplex and P-23 vaccine as 
a biological modifiers that could be used in the immune 
therapy of HNCA in particular and other cancers in 
general. 
It has been shown that all HNCA groups were 
immunosuppressed in comparison with HC subjects. 
Nasopharyngeal CA (NPC) patients have shown the 
lowest CM1 level, then CA larynx (CL) and finally hypo- 
pharyngeal CA patients (HPC). It is highly suggestive 
that immune suppression in NPC patients may be 
necessary to activate the latent phase of Epstein-Barr 
virus having said that 85% of NPC patients in Iraq 
caused by EBV which has been proved by another study 
that we conducted. 
The most important result of our study that it has 
been shown that both S2-complex and Pneumo-23 
vaccine were excellent immune-stimulatory agents in 
vitro, and they might be a powerful agents of the future 
immune-therapy against cancers in general and HNCA 
in particular. 
A comparative epidemiological study of NPC patients 
with other head and neck cancer (HNCA) patients in 
Iraqi population 
IDr. Ahmed Sahib Abd Al-Amir, ‘Professor Dr. Nidhal 
Abdul Muhaimen 
‘Microbiology Department, Saddam College of 
Medicine, Baghdad, Iraq 
An epidemiological case study has been conducted on 
142 different head and neck cancer (HNCA) patients in 
Iraqi population. Patients were examined at different 
stages of the disease, 8 different types of HNCA were 
covered by this study. But for statistical purposes we 
have taken only the 3 most common types of HNCA 
for conducting our comparative epidemiological study 
which were nasopharyngeal CA (NPC), CA larynx (CL), 
and hypopharyngeal CA (HPC). NPC group was our 
top interest due to the fact that it is largely caused by 
viral infection, Epstein Barr virus (EBV) in that EBV- 
caused NPC is not uncommon event in the middle east 
and this unique etiology makes NPC an interested group 
of HNCA. Epidemiological parameters taken were age, 
sex, histology of the disease, staging, smoking, alcohol 
intake. It has been found that each HNCA group has it’s 
own profile of risk factors, but some of risk factors were 
pan-affective for all HNCA groups. 
It has been shown that all HNCA patients of 
squamous cell carcinoma (SCC) except for NPC patients 
that have elicited a relatively large proportion of highly 
undifferentiated carcinoma, namely lymphoepithelioma 
(LE). The age of HNCA patients was ranging between 
16 to 74 years old and found that age in HNCA patients 
is not distinct for each type of HNCA and these differ- 
ences are due to chance factor. 
It has been shown that the sex ratio in HNCA patients 
is different from each other significantly (p<O.O05). In 
general male:female ratio was 2.6:1 and there was a 
clear male predominance in HNCA patients over 
females except in HPC patients. Also it was found that 
smoking is a very important risk factor for HNCA, 
especially for NPC group. Regarding alcohol intake it 
was found that HNCA patients in general not so largely 
affected by this factor except for NPC patients who 
have shown a great relation with the level of daily 
alcohol intake. Lastly, all HNCA groups have shown a 
good relation with the positive family history but this 
feature was poor in case of NPC patients which is 
may be due to fact that NPC is largely caused by 
environmental factors rather than inherited ones like 
EBV as viral etiological factor. 
In vitro activity of ertapenem against gram-negative 
bacilli isolated from blood stream infections in 
cancer patients 
George J. Alangaden, * Elias Manavathu, 
Jessica Cutright, Pranatharthi Chandrasekar 
*Wayne State University and the Karmanos 
Cancer Institute, Detroit, Michigan, USA 
The antimicrobial activity of ertapenem, a new long- 
acting carbapenem which can be dosed once daily, 
was tested against aerobic gram negative bacilli isolated 
from blood stream infections (BSI) in 156 cancer patients 
during the years 2000 and 2001. The MICs were deter- 
mined by NCCLS approved microdilution methods. The 
bacteria tested included 44 Klebsiella spp., 42 Escherichia 
coli, 19 Pseudomonas aeruginosa, 18 Enterobacter spp., 9 
Acinetobacter baumannii, 8 Citrobacter freundii, 5 
Proteus mirabilis, 4 Serratia marcescens, 3 Stenotropho- 
monas maltophilia, 2 Salmonella spp., and 2 Pantoea 
agglomerans. 
Ertapenem inhibited 75%, 80% and 83% of all 
isolates at concentrations of 1 pg/ml, 2 pg/ml and 4 
kg/ml respectively (breakpoint for susceptibility 58 
kg/ml). Ertapenem exhibited good activity against 
Klebsiella (MICgo <0.0625), E. coli (MI&, ~0.0625) 
Enterobacter (MIC90 0.5), Citrobacter (MICgo 52 
kg/ml), Proteus (MIC9o 0.125) Serratia (MTC90 0.0625) 
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Salmonella (MIGo ~0.0625) and Pantoea (~0.0625). 
Among the other organisms ertapenem inhibited 7/9 
strains of Acinetobacter at MIC 18 kg/ml, and O/3 strains 
of Stenotrophomonas at MIC 58 kg/ml. Thirteen of 
19 (68%) strains of Pseudomonas were susceptible to 
ertapenem - 2 strains MIC 1 &ml, 4 strains MIC 2 
kg/ml, 5 strains MIC 4 Fg/ml, 2 strains MIC 8 pg/ml and 
6 strains 116 kg/ml. Overall, ertapenem displayed good 
activity against common aerobic gram negative bacilli 
isolated from BSI in cancer patients. Thus ertapenem 
may be a potential candidate for the therapy of micro- 
biologically documented infections involving susceptible 
organisms in cancer patients. 
Unusual fungal infections in children with cancer 
L. A. Chong, H. Ariffin, K. Shekhar, WA. Ariffin, 
L. L. Chart, H. P Lin 
Paediatric Haematology-Oncology Unit, 
University Malaya Medical Center, Kuala Lumpur, 
Malaysia 
Introduction: Although Candida and Aspergillus are the 
predominant fungal pathogens in immunocompromised 
patients, over the last decade there has been an increase 
in the number of pathogens recognized as causing 
invasive diseases in this group of patients. We report 
on four patients with invasive Fusarium and Mucor 
infection seen in our unit in a five-year period between 
1996 and 2001 to illustrate the changing epidemiology of 
fungal infection in the immunocompromised host. 
Case reports: The first patient was an 8-year old girl with 
acute myeloid leukaemia who developed pyoderma 
gangrenosum-like skin lesions before succumbing to 
disseminated Fusarium infection and acute respiratory 
distress syndrome. The second patient was a 5-month 
old boy who developed pneumonia associated with a 
transient erythematous rash while on chemotherapy for 
congenital leukemia. Blood cultures grew Fusarium 
solani and he was treated successfully with 6 weeks of 
amphotericin B and granulocyte-macrophage colony 
stimulating factor. He died of the underlying malig- 
nancy six months later. The third patient was a 6-year 
old girl who developed a left facial and infraorbital 
cellulitis 6 months after completion of chemotherapy 
for acute lymphoblastic leukaemia. This infection led to 
erosion of her ethmoid and maxillary sinuses, nasal 
septum and palate. Mucor sp. was isolated from a 
maxillary sinus biopsy. She was treated with 60 days of 
amphotericin B and underwent two surgical debride- 
ments before achieving clinical and microbiological 
control. However while on weaning doses of ampho- 
tericin, she had a relapse of her leukaemia and 
recrudescence of Mucor infection. This led to a fatal 
extension to the brain.The fourth patient was a 9-month 
old boy who was having an unrelated cord blood 
transplant in his second clinical remission from infantile 
leukaemia. At day 34 post transplant he developed an 
Aspergillus tunnel infection of his Hickman catheter. 
This infection cleared with catheter removal, surgical 
drainage and amphotericin. On day 81 post transplant 
he developed left hypertonia and facial nerve palsy and 
a space-occupying lesion in the right basal ganglia was 
noted on radioimaging. This was rapidly fatal and 
Fusarium sp. was isolated from a post-mortem brain 
biopsy. 
Conclusions: Progress in the management of childhood 
cancer should be accompanied by improvement in 
therapy for infection. Rapid, accurate diagnosis of 
previously unrecognised pathogens and development of 
increased-spectrum anti-fungal agents are necessary to 
deal with these new, and often fatal, fungal infections. 
Cryptococcal central nervous system (CNS) infections 
in Norway 
Dug Torfoss*, Einar Sivertsen, Arne Hoiby, 
Bjorn Zversen 
*The Norwegian Radium Hospital, Oslo, Norway 
Cryptococcal CNS infections are rare in Norway. Only 
14 cases have been reported to The Norwegian Surveil- 
lance System for Communicable Diseases since 1987. 
Reporting of this infection has been mandatory in Norway 
in this period. 
We describe a patient with Hodgkins lymphoma who 
presented with cryptococcal meningoencephalitis. The 
patient responded to antifungal therapy but later died 
of his lymphoma. 
We also give a short presentation of the other 13 
reported cases comprising both AIDS patients and solid 
organ transplanted patients. 
Although cryptococcal CNS infections are rare, it is 
important to consider the diagnosis in patients with 
lymphoma and AIDS as well as in solid organ trans- 
planted patients, who present with new onset neuro- 
logical symptoms, since this is a treatable disease. 
Fluorquinolones prophylaxis in pediatric onco- 
hematological patients 
I? A. Chinello, S. Cesaro, C. Manzardo, S. Varotto, 
E. Calore, M. Pillon, R. Cusinato, R. D’Elia, C. Messina, 
L. Zanesco 
Clinic of Pediatric Hemato-Oncology, Microbiology 
Service, Service of Pediatric Infectious Disease on 
Immunocompromised Host, Department of Pediatrics, 
Padova, Italy 
Objective: Prophylaxis with fluorquinolones (PFQ) was 
introduced at our center during nineties for prevention 
of bacterial fever and sepsis in high-risk patients: 
i.e., patients who underwent hematopoietic stem cell 
transplantation (HSCT) or high-dose chemotherapy 
